First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET. (October 2020) - Hong, D.; Bazhenova, L.; Cho, B.C.; Sen, S.; Ponz-Sarvise, M.; Heist, R.; Zimmerman, Z.; Le, X.; Xuan, D.; Junming, Z.; Lee, J.